We report on a patient with hypoplastic left heart syndrome (HLHS), ventricular septal defects, and coronary sinusoids who suffered recurrent myocardial ischemic events that required cardiopulmonary resuscitation after stage I palliation. We identified the main reason to be a steal phenomenon of blood from the left coronary artery via the sinusoids into the rudimentary left ventricle and across the septal defects into the right ventricle. To limit this coronary steal phenomenon, we successfully performed transcatheter closure of the left ventricle with implantation of three Microplex Terumo®-Coils. This led to the patient s clinical stabilization. Stage II surgery took place at the age of 5 months without difficulty. In the setting of a symptomatic neonate with HLHS and ventriculocoronary connections, embolization of the left ventricle is a feasible interventional therapy. © 2012 Wiley Periodicals, Inc.
An 85-year-old man was recently admitted to our institution with congestive heart failure (New York Heart Association functional class III/IV) and hemolytic anemia. The patient had a prior history of Streptococcus viridans bacterial endocarditis that resulted in severe aortic and mitral regurgitations. In 2002, he underwent surgical aortic (Carpentier-Edwards #25, Edwards Lifesciences, Irvine, California) and mitral (Hancock modified #29, Medtronic, Minneapolis, Minnesota) valve replacements. Transesophageal echocardiogram (TEE) performed during the recent hospitalization showed that the left ventricular ejection fraction was 55%. The Hancock modified bioprosthesis in the mitral position was well seated, but there was severe mitral regurgitation caused by a flail leaflet ((Figure 18_gr1)A,Online Video 1). The mitral bioprosthesis was oval-shaped, and the internal diameters were measured to be 21 × 23.8 mm (Figure 18_gr1B). In addition, there was severe stenosis of the Carpentier-Edwards valve in the aortic position with an aortic valve area (AVA) of only 0.9 cm2. On 3-dimensional TEE, the internal diameter of the valve was measured to be 24 mm (Figure 18_gr2).
Patients who undergo transcatheter aortic valve implantation are generally discharged on dual-antiplatelet therapy. However, many of these patients also have indications for anticoagulant therapy, and it is unclear what the best antithrombotic strategy is in these cases. Data from 360 patients who underwent transcatheter aortic valve implantation were retrospectively analyzed, of whom 60 (16.7%) had indications for anticoagulant treatment, mainly because of atrial fibrillation. The antithrombotic regimen was decided according to clinical evaluation of thrombotic and hemorrhagic risk; most of these patients (n = 43) were discharged with warfarin plus a single antiplatelet drug. Their outcomes were compared to those in a group with no indications for anticoagulation (n = 300) treated with dual-antiplatelet therapy. During the follow-up period (median 11 months), 53 patients (15%) died; mortality was not associated with antithrombotic regimen. The incidence of cerebral events or intracranial hemorrhage (4.6% and 1.1%, respectively) was low in the study population, and no significant differences were detected between groups; the bleeding rate was also unaffected by antithrombotic therapy. In conclusion, when anticoagulation is indicated after transcatheter aortic valve implantation, many variables must be taken into account. The most frequent scenario in this study was patients in atrial fibrillation, most of whom were discharged with warfarin plus a single antiplatelet medication. When bleeding was a concern, especially in the absence of coronary disease, warfarin alone was prescribed. These results suggest that this approach is safe, but data from larger, randomized studies are needed.
Background: Limited evidence exists regarding the long-term performance of polymer-free (PF) drug-eluting stents (DES) in comparison to permanent polymer DES. This study investigated the 5-year efficacy and safety of a PF sirolimus-eluting stent (PF-SES) versus a permanent polymer paclitaxel-eluting stent (PES) in the setting of the Intracoronary Stenting and Angiographic Restenosis-Test Equivalence Between Two Drug-Eluting Stents (ISAR-TEST) randomized trial.
Background—The optimal duration of dual antiplatelet therapy (DAPT) after implantation of drug-eluting coronary stents remains undetermined. We aimed to test whether 6-month DAPT would be noninferior to 12-month DAPT after implantation of drug-eluting stents.
A 43-year-old woman with World Health Organization group I severe pulmonary hypertension, associated with systemic lupus erythematosus, was referred for cardiac catheterization as part of a lung transplant evaluation. She was also having anginal symptoms during walking. Physical examination was significant for a loud P2 and right ventricular lift. Coronary angiogram revealed a tight ostial left main (LM) stenosis (Figure 10_gr1A). (Online Video 1) thought due to compression by a markedly enlarged pulmonary artery (PA) ((Figure 10_gr1)A and (Figure 10_gr1)B, Online Video 1 and 2). This was confirmed by a coronary 64-slice multidetector computed tomography (Figure 10_gr1C). She underwent successful LM stenting with a 4 × 15-mm bare-metal stent. Since that time, she has had no recurrence of the angina. Follow-up coronary multidetector computed tomography was done at 5 months and confirmed patency of the stent (Figure 10_gr1D). Given the severity of the underlying disease, the patient continues to be evaluated for lung transplant.
There have been no optical coherence tomographic (OCT) data directly comparing the pattern of strut coverage between the 2 second-generation drug-eluting stents in the early period. The aim of this prospective study was to evaluate early strut coverage using optical coherence tomography 3 months after Resolute zotarolimus-eluting stent (ZES-R) or everolimus-eluting stent (EES) implantation in de novo coronary artery lesions. A total of 40 patients who were suitable for the OCT procedure and consented to the study protocol were randomized 1:1 to receive either ZES-R or EES. Among these patients, 35 stented lesions (18 ZES-R, 17 EES) in 34 patients were evaluated by optical coherence tomography immediately and 3 months after stent implantation. Neointimal hyperplasia thickness, percentage of uncovered struts, and the proportion of malapposed struts were measured at 1-mm intervals. An uncovered strut was defined as having a neointimal hyperplasia thickness of 0 μm. At the 3-month OCT evaluation, mean neointimal hyperplasia thickness (ZES-R vs EES 74 ± 41 vs 75 ± 35 μm, p = 0.89) and mean percentage of uncovered struts (ZES-R vs EES 6.2 ± 6.9 vs 4.7 ± 5.1%, p = 0.62) were not significantly different between the groups. The percentage of malapposed struts was also similar between the groups (0.7 ± 2.2% for ZES-R and 0.7 ± 1.7% for EES, p = 0.64). Thrombi were documented in 3 stents (1 [5.6%] in a ZES-R vs 2 [11.8%] in EES, p = 0.60). In conclusion, early stent strut coverage on the basis of serial OCT evaluation was comparable between ZES-R and EES 3 months after stent implantation.
Objective: We evaluated, using quantitative coronary angiography, the natural history of change that occurred in target lesions after successful sirolimus-eluting stent (SES) implantation.
A 4-year-old boy (body weight 14 kg) was referred to our department with the clinical diagnosis of patent ductus arteriosus for further evaluation and treatment. Besides a poor weight gain (body weight below the 10th percentile for age) and frequent respiratory infections, the patient was otherwise asymptomatic. Echocardiographic evaluation showed a dilated (for age) left ventricle with normal function. A connection between the origin of the right coronary artery and the right atrium was interpreted as a congenital arteriovenous fistula. Multislice computed tomography (MSCT) showed the presence of a tunnel-like communication between the right coronary sinus and the superior part of the right atrium (Figure 20_gr1). A narrowing was seen in the middle position of the communication. Cardiac catheterization and aortography performed under general anesthesia confirmed the findings of MSCT. The diameter of the stenosis was measured to be approximately 4.9 mm (Figure 20_gr2A). The tunnel was entered from the aorta using a 5-F right Judkins coronary catheter. Following the formation of an arteriovenous loop, a 5-mm (waist diameter) × 4-mm (length) Amplatzer Duct Occluder II (ADO II) (St. Jude Medical, St. Paul, Minnesota) was deployed through a 5-F sheath across the narrowed part of the tunnel ((Figure 20_gr2)B and Figure 20_gr2C).
An 82-year-old woman with severe aortic stenosis was referred to our center. Transcatheter aortic valve implantation (TAVI) was scheduled due to her high surgical risk (logistic EuroSCORE = 25.8%). The annulus diameter measured by transesophageal echocardiography (TEE) was 22.2 and 23.6 mm by multidetector computed tomography (CT). A 26-mm Edwards valve (Edwards Lifesciences, Irvine, California) was subsequently implanted via the transfemoral approach. After implantation, sudden hemodynamic collapse occurred, and aortography revealed contrast protrusion from the aortic cusp ((Figure 20_gr1)A,Online Video 1). Fluoroscopic detection of restricted heart motion with surrounding white area (Online Video 1) facilitated immediate diagnosis of tamponade before echocardiography. After percutaneous pericardial drainage via the subxiphoid approach and heparin neutralization, blood autotransfusion was performed via a circuit connecting the drainage catheter and the femoral vein sheath. Hemodynamics were stabilized within 30 min, and contrast protrusion disappeared (Online Video 2) Pre-procedural CT showed a calcified nodule (5 × 7.5 mm) at the epicardial fat segment between the interventricular septum and left atrium (Figure 20_gr1B, arrow), and contrast leakage was observed in post-procedural CT (Figure 20_gr1C, arrow). The patient was discharged on Day 8 without any complications. We successfully treated a similar case (with a 26-mm valve for the 22-mm TEE-measured annulus diameter) with contrast protrusion ((Figure 20_gr1)D, Online Videos 3 and 4) and similar pre- and post-CT findings ((Figure 20_gr1)E and Figure 20_gr1F).
Left ventricular (LV) dysfunction and multivessel disease (MVD) have been associated with greater mortality after ST-segment elevation myocardial infarction. The aim of this study was to evaluate the impact of LV dysfunction and MVD in patients with ST-segment elevation myocardial infarctions treated with primary percutaneous coronary intervention (PCI). Patients from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial treated with primary PCI in whom baseline LV function was assessed using left ventriculography were included in this study. Early and late (3-year) outcomes were examined in groups of patients with reduced (<40%) and preserved (≥40%) LV ejection fractions (LVEFs), further stratified by the presence of MVD. A total of 2,430 patients were included. Patients with reduced LVEFs were older; were more likely to be women; were more likely to have histories of myocardial infarction, PCI, and heart failure; and were more likely to present in heart failure. Patients with reduced LVEFs had greater 30-day (8.9% vs 0.9%, hazard ratio 9.81, 95% confidence interval 5.23 to 18.42, p <0.0001) and 3-year (17.1% vs 3.7%, hazard ratio 5.03, 95% confidence interval 3.37 to 7.50, p <0.0001) mortality. Among patients with LVEFs <30% (n = 45), 30% to 40% (n = 157), 40% to 50% (n = 373), 50% to 60% (n = 659), and ≥60% (n = 1,196), 3-year mortality was 29.4%, 13.5%, 6.4%, 3.8%, and 2.9%, respectively (p for trend <0.0001). MVD was associated with greater mortality in patients with preserved but not reduced LVEFs. By multivariate analysis, LV dysfunction was the strongest predictor of 30-day and 3-year mortality. In conclusion, the presence of LV dysfunction as assessed on baseline left ventriculography in patients who undergo primary PCI in the contemporary era is a powerful predictor of early and late mortality, regardless of the extent of coronary artery disease.
Objectives: The aim of this prospective, multicenter study was to assess the safety, feasibility, acceptance, and cost of ambulatory transradial percutaneous coronary intervention (PCI) under the conditions of everyday practice. Background: Major advances in PCI techniques have considerably reduced the incidence of post-procedure complications. However, overnight admission still constitutes the standard of care in most interventional cardiology centers. Methods: Eligibility for ambulatory management was assessed in 370 patients with stable angina referred to three high-volume angioplasty centers. On the basis of pre-specified clinical and PCI-linked criteria, 220 patients were selected for ambulatory PCI. Results: The study population included a substantial proportion of patients with complex procedures: 115 (52.3%) patients with multivessel coronary artery disease, 50 (22.7%) patients with multilesion procedures, and 60 (21.5%) bifurcation lesions. After 4-6 hr observation period, 213 of the 220 patients (96.8%) were cleared for discharge. The remaining seven (3.2%) patients were kept overnight for unstable angina (n = 1), atypical chest discomfort (n = 2), puncture site hematoma (n = 1), or non-cardiovascular reasons (n = 3). Within 24 hr after discharge, no patients experienced readmission, stent occlusion, recurrent ischemia, or local complications. Furthermore, 99% of patients were satisfied with ambulatory management and 85% reported no anxiety. The average non-procedural cost was lower for ambulatory PCI than conventional PCI (1,230 ± 98 Euros vs. 2,304 ± 1814 Euros, P < 10−6). Conclusions: Ambulatory PCI in patients with stable coronary artery disease is safe, effective, and well accepted by the patients. It may both significantly reduce costs and optimize hospital resource utilization. © 2012 Wiley Periodicals, Inc.
Background—Percutaneous interventions for chronic total occlusions have low success rates, primarily because of failure of guide wire crossing. Collagen-rich matrix constitutes the main barrier to chronic total occlusion crossing. In preclinical studies, local delivery of a bacterial collagenase formulation improved guide wire crossing. The Collagenase Total Occlusion-1 (CTO-1) Trial is a phase I, dose-escalation trial to assess the safety and efficacy of collagenase therapy to facilitate guide wire crossing in coronary artery chronic occlusions.
Background—Paravalvular regurgitation (PVR) is common after transcatheter aortic valve replacement (TAVR) and may be associated with adverse outcomes. Postdilatation (PD) has been proposed to treat PVR without being formally studied. We performed a study to evaluate the safety and efficacy of PD after balloon expandable TAVR.
Drug-eluting stents have shown promising clinical results in the treatment of coronary artery disease, including in women. Studies with first-generation drug-eluting stents, however, have reported higher rates of stent thrombosis (ST). The aim of this study was to evaluate the safety and efficacy of second-generation everolimus-eluting stents (EES) versus first-generation sirolimus-eluting stents (SES) in women. The study included 1,649 women; 1,152 (70%) received SES and 497 (30%) received EES. In-hospital and 1-, 6-, and 12-month clinical outcomes were analyzed and compared. Correlates of major adverse cardiac events and ST were identified. Baseline clinical characteristics were similar between stent types, although more peripheral vascular disease and family history of coronary artery disease were seen in the SES group, while more unstable angina pectoris at initial diagnosis was more prevalent in the EES group. The EES group had more type C and distal lesions. There was a higher rate of target vessel revascularization and major adverse cardiac events in the SES group (14.7% vs 10.8%, p = 0.04) at 1 year. ST tended to be higher in the SES group (1.5% vs 0.4%, p = 0.06) at 6 and 12 months. After adjustment, multivariate analysis indicated that the EES group was less likely to have target vessel revascularization and major adverse cardiac events (hazard ratio 0.67, 95% confidence interval 0.47 to 0.95, p = 0.024) and had lower rates of ST (hazard ratio 0.09, 95% confidence interval 0.01 to 0.70, p = 0.022) at 1 year. In conclusion, contemporary use of EES in women is associated with improvement in efficacy and safety profiles compared to SES; however, a large randomized trial is needed to confirm this conclusion.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos